Letter to the EditorEfficiency of sirolimus delivery to the skin is dependent on administration route and formulation
Section snippets
Funding sources
This study was supported by a grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan (16k10155) and grants from the Practical Research Project for Rare and Intractable Diseases from the Japan Agency for Medical Research and Development (AMED; 15ek0109082h0001, 16ek0109082h0002, 15Ik0109082h0002, and 16Ik0109082h0003).
Conflicts of interest
The authors have no conflict of interest to declare.
Acknowledgment
None.
References (9)
Mammalian target of rapamycin and tuberous sclerosis complex
J. Dermatol. Sci.
(2015)- et al.
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
Lancet (London, England)
(2013) - et al.
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
Lancet (London, England)
(2013) - et al.
Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus
J. Am. Acad. Dermatol.
(2015)
Cited by (6)
Pilot study for the treatment of cutaneous neurofibromas in neurofibromatosis type 1 patients using topical sirolimus gel
2023, Journal of the American Academy of DermatologyPolymeric micelle formulations for the cutaneous delivery of sirolimus: A new approach for the treatment of facial angiofibromas in tuberous sclerosis complex
2021, International Journal of PharmaceuticsCitation Excerpt :As other formulations were highly lipophilic and could form a residual oily film on a patient’s face, hydrogels were prepared in order to increase patient compliance. However, due to the poor aqueous solubility of SIR, all of these formulations contained a considerable amount of alcohol (Kitayama et al., 2019; Le Guyader et al., 2018; Wataya-Kaneda et al., 2017a). This excipient is a well-known solubilizer and a penetration enhancer.
Treatment with sirolimus gel for folliculocystic and collagen hamartoma in tuberous sclerosis complex
2021, Dermatologica Sinica